114 related articles for article (PubMed ID: 6128469)
1. Different effects of thromboxane synthetase inhibitors on platelets from different individuals.
Lancet; 1982 Nov; 2(8308):1156-7. PubMed ID: 6128469
[No Abstract] [Full Text] [Related]
2. Inhibition of arachidonate-induced human platelet aggregation by a single low oral dose of aspirin in combination with a thromboxane synthase inhibitor.
Cerletti C; Rajtar G; Bertelé V; de Gaetano G
Thromb Haemost; 1984 Oct; 52(2):215. PubMed ID: 6441306
[No Abstract] [Full Text] [Related]
3. Lag-phase of arachidonic acid-induced secretion in responders and non-responders to the thromboxane-synthetase inhibitors: involvement of cyclic-AMP.
Lecompte T; Joussemet M; Hainaut J
Thromb Res; 1984 Jul; 35(1):91-7. PubMed ID: 6089368
[No Abstract] [Full Text] [Related]
4. Inhibition of platelet aggregation by 1-alkylimidazole derivatives, thromboxane A synthetase inhibitors.
Kayama N; Sakaguchi K; Kaneko S; Kubota T; Fukuzawa T; Kawamura S; Yoshimoto T; Yamamoto S
Prostaglandins; 1981 Apr; 21(4):543-54. PubMed ID: 7196056
[TBL] [Abstract][Full Text] [Related]
5. Thromboxane synthetase inhibition as antithrombotic strategy.
Vermylen J; Defreyn G; Carreras LO; Machin SJ; Van Schaeren J; Verstraete M
Lancet; 1981 May; 1(8229):1073-5. PubMed ID: 6112447
[TBL] [Abstract][Full Text] [Related]
6. UK-37, 248, a novel, selective thromboxane synthetase inhibitor with platelet anti-aggregatory and anti-thrombotic activity.
Randall MJ; Parry MJ; Hawkeswood E; Cross PE; Dickinson RP
Thromb Res; 1981 Jul 1-15; 23(1-2):145-62. PubMed ID: 6795753
[No Abstract] [Full Text] [Related]
7. Platelet thromboxane synthetase inhibitors with low doses of aspirin: possible resolution of the "aspirin dilemma".
Bertelé V; Falanga A; Tomasiak M; Dejana E; Cerletti C; de Gaetano G
Science; 1983 Apr; 220(4596):517-9. PubMed ID: 6682245
[TBL] [Abstract][Full Text] [Related]
8. Biochemical and pharmacological evaluation of thromboxane synthetase inhibitors.
Gorman RR
Adv Prostaglandin Thromboxane Res; 1980; 6():417-25. PubMed ID: 6247892
[No Abstract] [Full Text] [Related]
9. Comparison of the effects of selective inhibition of thromboxane synthase with those of inhibition of the cyclooxygenase enzyme in man.
Oates JA; Brash A; Fitzgerald G
Trans Am Clin Climatol Assoc; 1984; 95():157-62. PubMed ID: 6433527
[No Abstract] [Full Text] [Related]
10. Biology and biochemistry of thromboxane synthetase inhibitors.
Gorman RR
Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():235-40. PubMed ID: 6221529
[No Abstract] [Full Text] [Related]
11. Pharmacological studies on OKY-1581: a selective thromboxane synthetase inhibitor.
Hiraku S; Wakitani K; Katsube N; Kawasaki A; Tsuboshima M; Naito J; Ujiie A; Komatsu H; Iizuka K
Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():241-4. PubMed ID: 6221530
[No Abstract] [Full Text] [Related]
12. Thromboxane synthetase inhibitors as pharmacological tools: differential biochemical and biological effects on platelet suspensions.
Needleman P; Bryan B; Wyche A; Bronson SD; Eakins K; Ferrendelli JA; Minkes M
Prostaglandins; 1977 Nov; 14(5):897-907. PubMed ID: 594391
[TBL] [Abstract][Full Text] [Related]
13. Effect of SQ 80,338 (1-(3-phenyl-2-propenyl)-1H-imidazole) on thromboxane synthetase activity and arachidonic acid-induced platelet aggregation and bronchoconstriction.
Harris DN; Greenberg R; Phillips MB; Osman GH; Antonaccio MJ
Adv Prostaglandin Thromboxane Res; 1980; 6():437-41. PubMed ID: 7189949
[No Abstract] [Full Text] [Related]
14. Inhibition of thromboxane synthetase does not necessarily prevent platelet aggregation.
Bartele V; Cerletti C; Schiepatti A; di Minno G; de Gaetano G
Lancet; 1981 May; 1(8228):1057-8. PubMed ID: 6112437
[No Abstract] [Full Text] [Related]
15. Thromboxane synthetase inhibition results in increased platelet sensitivity to prostacyclin.
Bertelé V; Falanga A; Roncaglioni MC; Cerletti C; de Gaetano G
Thromb Haemost; 1982 Jun; 47(3):294. PubMed ID: 7051411
[No Abstract] [Full Text] [Related]
16. A comparison of imidazole and 9,11-azoprosta-5,13-dienoic acid. Two selective thromboxane synthetase inhibitors.
Fitzpatrick FA; Gorman RR
Biochim Biophys Acta; 1978 Mar; 539(2):162-72. PubMed ID: 629996
[TBL] [Abstract][Full Text] [Related]
17. Effect of the thromboxane synthetase inhibitor UK-37,248 (dazoxiben) upon platelet aggregation, coronary artery thrombosis and vascular reactivity.
Schumacher WA; Lucchesi BR
J Pharmacol Exp Ther; 1983 Dec; 227(3):790-6. PubMed ID: 6418881
[TBL] [Abstract][Full Text] [Related]
18. The effect of a thromboxane synthetase inhibitor, dazoxiben, and acetylsalicylic acid on platelet function and prostaglandin metabolism.
Dale J; Thaulow E; Myhre E; Parry J
Thromb Haemost; 1983 Oct; 50(3):703-6. PubMed ID: 6689091
[TBL] [Abstract][Full Text] [Related]
19. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism.
Gresele P; Arnout J; Deckmyn H; Huybrechts E; Pieters G; Vermylen J
J Clin Invest; 1987 Nov; 80(5):1435-45. PubMed ID: 2960694
[TBL] [Abstract][Full Text] [Related]
20. Platelet aggregation in whole blood: the role of thromboxane A2 and adenosine diphosphate.
Carter AJ; Heptinstall S
Thromb Haemost; 1985 Oct; 54(3):612-6. PubMed ID: 3937261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]